You get what you pay for, in a sense. How would the public respond to a one-time cure being sold for more than the total lifetime cost of treatment? Not well, but the thing is that responding like that is effectively expressing a preference for the lifelong treatment.
It’s not an imaginary scenario. For example, look at Sovaldi, the $84,000 hepatitis C cure. That’s less than the total cost of long-term treatment but it didn’t exactly make Gilead popular.
the other big thing is that for most with chronic illnesses, the public isn’t looking, nor do they care, if i had the money, i would try anything, but i hardly leave my house and i can’t afford to work, so i’ll take whatever my insurance covers even if that ininofitself decreases my lifespan and causes me pain, hey actually, you just reminded me of a cure that “the public” doesn’t talk much about, when will euthanasia be legal? oh but that also is an abrupt end to a condition that could still be squeezed for profit, do you know your audience?
You get what you pay for, in a sense. How would the public respond to a one-time cure being sold for more than the total lifetime cost of treatment? Not well, but the thing is that responding like that is effectively expressing a preference for the lifelong treatment.
Are you trying to be Devil’s Advocate for an imaginary scenario? WTF
It’s not an imaginary scenario. For example, look at Sovaldi, the $84,000 hepatitis C cure. That’s less than the total cost of long-term treatment but it didn’t exactly make Gilead popular.
the other big thing is that for most with chronic illnesses, the public isn’t looking, nor do they care, if i had the money, i would try anything, but i hardly leave my house and i can’t afford to work, so i’ll take whatever my insurance covers even if that ininofitself decreases my lifespan and causes me pain, hey actually, you just reminded me of a cure that “the public” doesn’t talk much about, when will euthanasia be legal? oh but that also is an abrupt end to a condition that could still be squeezed for profit, do you know your audience?